InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the detailed record of transactions filed by Eansor Norman David, Chief Executive Officer. Officer active across 3 companies, notably Marker Therapeutics, Inc.. Aggregated, 8 filings have been logged. Total volume traded: €1.3m. The latest transaction was filed on 12 November 2021 — Levée d'options. Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
€3m27,159 shares@ €109.20620.044% mcap81.9% of flow
Common Stock
SEC:0000914190-21-000405·
€3m27,159 shares@ €109.20620.044% mcap41.0% of flow
Common Stock
SEC:0000914190-21-000405:0·
€655,1311,538 shares@ €425.96270.0097% mcap18.1% of flow
Common Stock
SEC:0000914190-21-000322·
€655,1311,538 shares@ €425.96270.0097% mcap9.0% of flow
Common Stock
SEC:0000914190-21-000322:0·
02,537 shares0
Common Stock
SEC:0000914190-21-000213·
02,537 shares0
Common Stock
SEC:0000914190-21-000213:0·
012,658 shares0
Common Stock
SEC:0001209191-21-039631:0·
012,658 shares0
Common Stock
SEC:0001209191-21-039631·
8 of 8 declarations
About Eansor Norman David
Norman David Eansor serves as CEO and President of Protein Sciences at Marker Therapeutics, Inc. and Bio-Techne Corp. In these roles, he is responsible for the strategic and operational direction of the companies. His expertise in the biopharmaceutical sector enables him to drive innovation and enhance the services offered. He plays a key role in achieving growth objectives and developing strategies aimed at strengthening the companies' market position.
